DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram’s™ efficacy to that of Cutivate® cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic dermatitis (AD).
